| |
| |
|
| Insider
Information: |
Kakkis Emil D |
| Relationship: |
|
| City: |
Novato |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
603,534 |
|
|
Indirect Shares
|
2,268,639 |
|
|
| Direct
Value |
$26,857,607 |
|
|
|
Indirect Value
|
$94,141,463 |
|
|
| Total
Shares |
2,872,173 |
|
|
| Total
Value |
$120,999,070 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Biomarin Pharmaceutical Inc |
BMRN |
Chief Medical Officer |
2009-03-02 |
39,621 |
2009-03-02 |
4,654 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
|
2024-03-01 |
563,913 |
2024-03-01 |
2,263,985 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
106 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2009-03-02 |
4 |
AS |
$11.70 |
$92,396 |
D/D |
(7,897) |
39,621 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2020-06-01 |
4 |
D |
$69.38 |
$92,553 |
D/D |
(1,334) |
611,041 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Business Operations |
• – – |
2004-05-06 |
4 |
B |
$6.48 |
$97,400 |
I/I |
15,000 |
26,110 |
1.99 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-11-03 |
4 |
OE |
$6.13 |
$98,080 |
D/D |
16,000 |
131,621 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2021-05-06 |
4 |
D |
$115.71 |
$98,585 |
D/D |
(852) |
595,200 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
CHIEF MEDICAL OFFICER |
• – – |
2008-12-01 |
4 |
OE |
$6.13 |
$104,210 |
D/D |
17,000 |
56,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical officer |
• – – |
2009-01-02 |
4 |
OE |
$6.13 |
$107,335 |
D/D |
17,000 |
56,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2009-02-03 |
4 |
OE |
$6.43 |
$109,310 |
D/D |
17,000 |
56,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-10-01 |
4 |
OE |
$6.13 |
$110,340 |
D/D |
18,000 |
133,304 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2019-03-01 |
4 |
D |
$67.55 |
$189,275 |
D/D |
(2,802) |
467,670 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2019-03-05 |
4/A |
S |
$65.52 |
$189,353 |
D/D |
(2,890) |
467,583 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2006-01-04 |
4 |
OE |
$4.00 |
$200,000 |
D/D |
50,000 |
88,144 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2019-09-11 |
4 |
B |
$43.63 |
$218,150 |
D/D |
5,000 |
472,479 |
2.81 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
CHIEF MEDICAL OFFICER |
• – – |
2008-12-01 |
4 |
AS |
$15.87 |
$269,790 |
D/D |
(17,000) |
39,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-04-01 |
4 |
AS |
$35.65 |
$291,120 |
D/D |
(8,143) |
96,021 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical officer |
• – – |
2009-01-02 |
4 |
AS |
$17.57 |
$298,690 |
D/D |
(17,000) |
39,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-04-29 |
4 |
OE |
$4.00 |
$300,000 |
D/D |
75,000 |
161,164 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-11-03 |
4 |
OE |
$18.11 |
$307,938 |
D/D |
17,000 |
114,621 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2009-02-03 |
4 |
AS |
$19.14 |
$325,373 |
D/D |
(17,000) |
39,621 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2023-10-19 |
4 |
OE |
$6.86 |
$328,272 |
D/D |
47,853 |
647,029 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-04-01 |
4 |
AS |
$35.71 |
$353,835 |
D/D |
(9,857) |
86,164 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2020-03-01 |
4 |
D |
$56.08 |
$386,728 |
D/D |
(6,896) |
504,800 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2017-08-28 |
4 |
B |
$52.40 |
$393,922 |
I/I |
7,500 |
2,559,741 |
2.66 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
President & CEO |
• • – |
2020-03-12 |
4 |
OE |
$3.01 |
$449,998 |
D/D |
149,700 |
654,500 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
Chief Medical Officer |
• – – |
2008-10-01 |
4 |
AS |
$26.27 |
$472,878 |
D/D |
(18,000) |
115,304 |
0 |
- |
|
106 Records found
|
|
Page 3 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
